PriceTargets.com logo

Delcath Systems - DCTH Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.00
  • Forecasted Upside: 332.69%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$4.16 As of 09/21/2023 01:00 AM ET
▼ -0.2 (-4.59%)

This chart shows the closing price for DCTH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Delcath Systems Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DCTH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DCTH

Analyst Price Target is $18.00
▲ +332.69% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Delcath Systems in the last 3 months. The average price target is $18.00, with a high forecast of $21.00 and a low forecast of $13.00. The average price target represents a 332.69% upside from the last price of $4.16.

This chart shows the closing price for DCTH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Delcath Systems. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/30/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/28/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/26/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/25/2022
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/22/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2023

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/7/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$18.00 ➝ $21.00Low
8/16/2023Roth MkmBoost TargetBuy ➝ Buy$10.00 ➝ $13.00Low
8/15/2023BTIG ResearchBoost TargetBuy ➝ Buy$19.00 ➝ $20.00Low
8/15/2023HC WainwrightBoost TargetBuy ➝ Buy$17.00 ➝ $18.00Low
8/15/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$14.00 ➝ $18.00Low
3/28/2023HC WainwrightLower TargetBuy$19.00 ➝ $17.00Low
11/21/2022Canaccord Genuity GroupLower Target$17.00 ➝ $14.00Low
11/15/2022BTIG ResearchLower Target$19.00N/A
8/10/2022HC WainwrightLower TargetBuy$25.00 ➝ $19.00Low
6/24/2022BTIG ResearchLower TargetBuy$23.00 ➝ $20.00Low
4/11/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$24.00 ➝ $20.00Low
12/10/2021HC WainwrightInitiated CoverageBuy$25.00Medium
5/11/2021BTIG ResearchReiterated RatingBuy$23.00Low
4/6/2021Roth CapitalBoost TargetBuy$20.00 ➝ $25.00Medium
1/5/2021BTIG ResearchInitiated CoverageBuy$23.00N/A
1/4/2021BTIG ResearchInitiated CoverageBuy$23.00N/A
6/4/2020Roth CapitalReiterated RatingBuyLow
6/4/2020Roth CapitalInitiated CoverageBuy$20.00High
6/1/2020LaidlawInitiated CoverageBuy$19.00High
(Data available from 9/21/2018 forward)

News Sentiment Rating

0.70 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/23/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
3/25/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/24/2023
  • 1 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/24/2023
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/23/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/23/2023
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/22/2023
  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/21/2023

Current Sentiment

  • 2 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Delcath Systems logo
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
Read More

Today's Range

Now: $4.16
Low: $4.10
High: $4.35

50 Day Range

MA: $4.64
Low: $3.12
High: $5.75

52 Week Range

Now: $4.16
Low: $2.34
High: $7.99

Volume

396,897 shs

Average Volume

811,924 shs

Market Capitalization

$63.56 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Delcath Systems?

The following equities research analysts have issued research reports on Delcath Systems in the last twelve months: BTIG Research, Canaccord Genuity Group Inc., HC Wainwright, Roth Mkm, and StockNews.com.
View the latest analyst ratings for DCTH.

What is the current price target for Delcath Systems?

4 Wall Street analysts have set twelve-month price targets for Delcath Systems in the last year. Their average twelve-month price target is $18.00, suggesting a possible upside of 332.7%. Canaccord Genuity Group Inc. has the highest price target set, predicting DCTH will reach $21.00 in the next twelve months. Roth Mkm has the lowest price target set, forecasting a price of $13.00 for Delcath Systems in the next year.
View the latest price targets for DCTH.

What is the current consensus analyst rating for Delcath Systems?

Delcath Systems currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DCTH will outperform the market and that investors should add to their positions of Delcath Systems.
View the latest ratings for DCTH.

What other companies compete with Delcath Systems?

Other companies that are similar to Delcath Systems include BrainsWay, Lucid Diagnostics, InspireMD, Pro-Dex and Rosecliff Acquisition Corp I. Learn More about companies similar to Delcath Systems.

How do I contact Delcath Systems' investor relations team?

Delcath Systems' physical mailing address is 1633 BROADWAY SUITE 22C, NEW YORK NY, 10019. The company's listed phone number is 212-489-2100 and its investor relations email address is investorrel[email protected]. The official website for Delcath Systems is delcath.com. Learn More about contacing Delcath Systems investor relations.